FDA Approves Oral PCSK9 Inhibitor for Cholesterol Reduction

Why it matters locally: The approval of this new oral medication for cholesterol reduction could impact healthcare providers and patients across South Dakota, offering an additional treatment option for hypercholesterolemia. Access to and coverage of this new drug will be a consideration for healthcare systems and insurance providers serving the state's population.

WASHINGTON – The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide) for the reduction of low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia. This medication represents the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Doctors will prescribe Lipfendra as an addition to diet and exercise regimens. The FDA's decision provides a new treatment option for individuals working to manage their cholesterol levels.